  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.19   
 
 
 
 
THE HOSPI[INVESTIGATOR_686178] (HAS-QOL)  
 
 
Principal Investigator  
  
[INVESTIGATOR_686179], PhD, RN, FAAN, FPCN 
NYU Rory Meyers College of Nursing 
[ADDRESS_930272], Room 504 
[LOCATION_001], NY [ZIP_CODE] 
[PHONE_9593] 
[EMAIL_8787] 
 
 
Co-Investigators  
Tara Cortes, PhD 
NYU Rory Meyers College of Nursing 
[ADDRESS_930273], Room 502 
[LOCATION_001], NY [ZIP_CODE] 
[PHONE_14292] 
[EMAIL_13122]  
 
Bei Wu, PhD 
NYU Rory Meyers College of Nursing 
[ADDRESS_930274], Room 520 
[LOCATION_001], NY [ZIP_CODE] 
[PHONE_14293] 
[EMAIL_13123]  
 
Keith Goldfeld, PhD 
NYUSOM Population Health 
[ADDRESS_930275] 
[LOCATION_001], NY [ZIP_CODE] 
[PHONE_14294] 
[EMAIL_13124]  
 
 
NYULMC Study Number 
 18-[ZIP_CODE] 
 
Funding Sponsor 
  
National Institutes of Health 
 
ClinicalTrials.gov Number     
             [STUDY_ID_REMOVED] 
 
Initial version: 3.28.19  
  
 
Study Number:  18-[ZIP_CODE]   Page ii 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.19   
Statement of Compliance 
 
This study will be conducted in accordance with the Code of Federal Regula tions on the Protection of 
Human Subjects (45 CFR Part 46), any other applicable US go vernment research regulations, and 
institutional research policies and procedures . The Principal Investigator [INVESTIGATOR_7433], 
or changes to the protocol will take place without prior agreement fr om the sponsor and documented 
approval from the Institutional Review Board (IRB), except where necessa ry to eliminate an immediate 
hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human 
Subjects Protection Training. 
  
Study Number:  18-[ZIP_CODE]   Page iii 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.[ADDRESS_930276] OF ABBREVIATIONS ........................................................................................................................  VI 
PROTOCOL SUMMARY ...............................................................................................................................  8 
1 KEY ROLES ........................................................................................................................................  10 
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE .....................  10 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ..............................................................  10 
2.1.1  DSM-H ....................................................................................................................................  10 
2.1.2  Provision of Hospi[INVESTIGATOR_6125] ..............................................................................................................  11 
2.1.3  Hospi[INVESTIGATOR_686180] P WD leading to sub-optimal 
outcomes .............................................................................................................................................  11 
2.1.4  Hospi[INVESTIGATOR_686181] ...........................................  11 
2.1.5  Behavioral and Psychological Symptoms of Dementia (BPSD) are ineffectively tr eated ..... [ADDRESS_930277] not focused 
on advanced dementia care or hospi[INVESTIGATOR_6125] ..............................................................................................  13 
2.1.11  Existing relevant interventions ...............................................................................................  13 
2.2 NAME [CONTACT_457685] ...............................................  13 
2.2.1  Champi[INVESTIGATOR_686182] ................................................................................................................  14 
2.2.2  Non-champi[INVESTIGATOR_457582] .............................................................................................  14 
2.2.3  HHA training ...........................................................................................................................  14 
2.2.4  Validated instruments .............................................................................................................  14 
2.2.5  Interprofessional care plans ...................................................................................................  15 
2.2.6  BPSD treatment algorithm .....................................................................................................  15 
2.3 CLINICAL DATA TO DATE ...............................................................................................................  15 
2.3.1  Development and Implementation of the DSM-H for Home Healthcare. ...............................  15 
2.3.2  Conversion of the DSM-H for Home Hospi[INVESTIGATOR_6125] ........................................................................  16 
2.4 RATIONALE  ...................................................................................................................................  16 
2.5 POTENTIAL RISKS & BENEFITS  ......................................................................................................  16 
Known Potential Risks ........................................................................................................................  16 
2.5.1  Known Potential Benefits .......................................................................................................  17 
3 OBJECTIVES AND PURPOSE ..........................................................................................................  17 
3.1 PRIMARY OBJECTIVES  ...................................................................................................................  17 
4 STUDY DESIGN AND ENDPOINTS ..................................................................................................  17 
4.1 DESCRIPTION OF STUDY DESIGN  ...................................................................................................  17 
4.1.1  Aim 1: Establish the infrastructure to implement a pragmatic clinical tria l of the DSM- H 
Hospi[INVESTIGATOR_686183]. ..................................................................................................................................  17 
4.1.2  Aim 2: Tailor the DSM-H Hospi[INVESTIGATOR_686184]-scale implementation in hospi[INVESTIGATOR_6125]. ...............................................................  19 
4.1.3  Aim 3: Pi[INVESTIGATOR_686185]-H Hospi[INVESTIGATOR_686186]  2 hospi[INVESTIGATOR_686187]. ..................................................................  19 
4.1.4  Additional activities .................................................................................................................  20 
4.2 STUDY ENDPOINTS  .......................................................................................................................  20 
4.2.1  Milestones ..............................................................................................................................  20 
5 STUDY ENROLLMENT ......................................................................................................................  21 
Study Number:  18-[ZIP_CODE]   Page iv 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.19  5.1 INCLUSION CRITERIA  .....................................................................................................................  21 
5.2 EXCLUSION CRITERIA  ....................................................................................................................  21 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  ..........................................................................  21 
5.3.1  Clinicians ................................................................................................................................  21 
5.3.2  Persons with Dementia ..........................................................................................................  21 
5.4 TOTAL NUMBER OF PARTICIPANTS AND SITES ................................................................................  22 
5.5 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................................................................  22 
5.5.1  Reasons for Withdrawal or Termination ................................................................................  22 
5.5.2  Handling of Participant Withdrawals or Termination ..............................................................  22 
6 STUDY QUALITY IMPROVEMENT PROGRAM ...............................................................................  22 
6.1 STUDY BEHAVIORAL OR SOCIAL QUALITY IMPROVEMENT PROGRAM  ................................................  22 
6.1.1  Procedures for Training Quality Improvement Teams and Monitoring  Fidelity .....................  22 
7 STUDY PROCEDURES AND SCHEDULE ........................................................................................  23 
7.1 STUDY PROCEDURES /EVALUATIONS  ..............................................................................................  [ADDRESS_930278] ................................................................................................ . 24 
7.2.5  Withdrawal/Early Termination Visit ........................................................................................  24 
8 ASSESSMENT OF SAFETY ..............................................................................................................  25 
8.1 STAFF (CLINICIANS ) ......................................................................................................................  25 
8.2 PERSONS WITH DEMENTIA  .............................................................................................................  25 
8.2.1  Data Safety and Monitoring ...................................................................................................  25 
8.2.2  Frequency and Reporting .......................................................................................................  25 
9 CLINICAL MONITORING ...................................................................................................................  25 
10 STATISTICAL CONSIDERATIONS ...................................................................................................  25 
10.1 STATISTICAL AND ANALYTICAL PLANS (SAP) ..................................................................................  25 
10.2 STATISTICAL HYPOTHESES  ............................................................................................................  25 
10.3 ANALYSIS DATASETS .....................................................................................................................  26 
10.4 DESCRIPTION OF STATISTICAL METHODS  .......................................................................................  26 
10.4.1  General Approach ..................................................................................................................  26 
10.4.2  Adherence and Retention Analyses .......................................................................................  26 
10.5 SAMPLE SIZE ................................................................................................................................  26 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS ................................ . 26 
12 QUALITY ASSURANCE AND QUALITY CONTROL ........................................................................  27 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS .............................................................................  [ADDRESS_930279]  .....................................................................................................  27 
13.3 INFORMED CONSENT PROCESS  .....................................................................................................  27 
13.3.1  Consent/Assent-PWD ............................................................................................................  [ADDRESS_930280] KEEPI[INVESTIGATOR_1645] ...................................................................................  28 
Study Number:  18-[ZIP_CODE]   Page v 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.[ADDRESS_930281] POLICY ...................................................................................................  30 
18 REFERENCES ....................................................................................................................................  31 
19 ATTACHMENTS ................................................................................................................................ . 36 
20 ANCILLARY STUDY ..........................................................................................................................  36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Study Number:  18-[ZIP_CODE]   Page vi 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.[ADDRESS_930282] Alzheimer’s Disease and Related Disorders  
AE Adverse Event/Adverse Experience 
BPSD  Behavioral and Psychological Symptoms of Dementia 
CFR Code of Federal Regulations 
CRF Case Report Form 
DHHS  Department of Health and Human Services 
DSM-H Dementia Symptom Management at Home Program 
DSKA Dementia Symptom Knowledge Assessment 
DSMB Data and Safety Monitoring Board 
FFR Federal Financial Report 
FWA Federalwide Assurance 
GCP Good Clinical Practice 
HHA  Home Health Aide 
 
HHC  Home Healthcare 
HIPAA Health Insurance Portability and Accountability Act 
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
IDT Interdisciplinary Team 
IRB Institutional Review Board 
MOP Manual of Procedures 
N Number (typi[INVESTIGATOR_33891]) 
NIA National Institute on Aging 
NIH National Institutes of Health 
NPI-Q Neuropsychiatric Inventory Questionnaire 
OHRP Office for Human Research Protections 
OHSR Office of Human Subjects Research 
PI [INVESTIGATOR_686188]/Serious Adverse Experience 
SOP Standard Operating Procedure 
US [LOCATION_002] 
 
Study Number:  18-[ZIP_CODE]   Page vii 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as 
authorized in writing by [CONTACT_553748]: 3.28.19   
Study Number:  18-[ZIP_CODE]   Page 8 
Version Date: 8/29/2018    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 05 JAN 2017  
 Protocol Summary 
Title  
The Hospi[INVESTIGATOR_686189] (HAS-QOL) 
Brief Summary  
As the population ages, the incidence rate of Alzheimer’s Disease and 
Related Disorders (dementia) is expected to triple. The National Alzheimer’s 
Plan recognizes that while the number of persons with dementia (PWD) is  
increasing substantially, the healthcare and long term care systems are 
unprepared to provide high quality, effective and efficient care to the PWD 
and their caregivers. PWD often have many behavioral and psychologica l 
symptoms of dementia (BPSD) including agitation, depression and sleep 
disturbances, that affect both the quality of life of the PWD and the car egiver. 
Unfortunately, due to a lack of programs to insert evidence-based care  into 
the community, and hospi[INVESTIGATOR_686190], PWD receive inappropriate 
and even harmful care. We have developed the Dementia Symptom 
Management at Home (DSM-H) Program to implement dementia friendly  
care for PWD and their caregivers in the community. Initially developed fo r 
use in home healthcare, we have modified the program for use in hospi[INVESTIGATOR_6125]. 
The DSM-H Hospi[INVESTIGATOR_686191] a systems level change program that 
includes workforce training, and agency level workflow changes.  
Objectives  
Through the 1-year R61 phase we will accomplish the following: 
Aim 1: Establish the infrastructure to implement a pragmatic clinical trial of th e 
DSM-H Hospi[INVESTIGATOR_686183]. We will establish a steering committee that will 
oversee all facets of the trial and integrate the work of the following wo rk 
groups: 1. Intervention refinement; 2. Intervention implementation; 3. 
Measurement; 4.Statistical methods; 5. Data management; 6. Stakeholders; 
7. Human subjects and data safety. 
 
Aim 2: Tailor the DSM-H Hospi[INVESTIGATOR_686192]-scale implementation in 
hospi[INVESTIGATOR_6125]. We will further refine the intervention focusing specifically 
on ensuring the following: 1. The content and training align specifically w ith 
hospi[INVESTIGATOR_686193]; 2. The content ca n 
be implemented in a wide-scale fashion in hospi[INVESTIGATOR_441698]. 
 
Aim 3: Pi[INVESTIGATOR_686185]-H Hospi[INVESTIGATOR_686186] [ADDRESS_930283] study  
Endpoint None 
Study Duration 1 year 
Study Number:  18-[ZIP_CODE]   Page 9 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  Participant Duration 1 month 
Population Hospi[INVESTIGATOR_686194] (RNs, Social Workers, Chaplains) 
Persons with dementia newly admitted for hospi[INVESTIGATOR_3677]. 
Study Sites  
This is a single site study with NYU being the only site. Study activities will 
take place at MJHS Hospi[INVESTIGATOR_686195]. 
 
Number of participants [ADDRESS_930284] whether the hospi[INVESTIGATOR_686196]. 
Statistical Analysis Persons with dementia: Descriptive Statistics 
Clinicians: descriptive statistics and Paired t-tests 
 
  
Study Number:  18-[ZIP_CODE]   Page 10 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930285], Room 504 
[PHONE_9593] 
[EMAIL_8787] 
 
 
 
[ADDRESS_930286] both 
persons with dementia (PWD) and their caregivers 1,2. In the advanced stage, the PWD becomes eligible for 
hospi[INVESTIGATOR_6125], whose goal is to alleviate suffering through symptom and p sychosocial care delivered by [CONTACT_686330] (IDT). Hospi[INVESTIGATOR_686197] ( 1-2 visits/week, more than 95% of hospi[INVESTIGATOR_209934] 3), continuous care (24h/d in-home nursing during symptom cris es), inpatient care (when advanced 
symptoms require intensive management), and respi[INVESTIGATOR_4594] (when caregivers need respi[INVESTIGATOR_686198], 
usually in a nursing home). Continuous care has been shown to significantly reduce inpatient care use and 
hospi[INVESTIGATOR_34380], allowing for more hospi[INVESTIGATOR_686199] 4,5. Professional quality, job satisfaction, 
burnout and turnover are important for interdisciplinary hospi[INVESTIGATOR_6125] c are workers. 1 
 
Hospi[INVESTIGATOR_686200], but of the 1.4 million hospi[INVESTIGATOR_686201], 16.5% have a principal diagnosis of dementia 3. PWD have the longest hospi[INVESTIGATOR_686202] (Mean 
105 days, Median 56 days) and make up an outsized portion of spending  (23.9%) 3.  Evidence-based practices 
exist for managing behavioral and psychological symptoms of dementia  (BPSD), such as aggression and 
depression, but they have not been implement ed, reducing hospi[INVESTIGATOR_6125]’s effectiveness in supporting PWD and 
caregivers 6. Hospi[INVESTIGATOR_686203] (prescribed in 64.6% of cases) 7, which are usually 
ineffective at treating BPSD, cause serious adverse events, and can re duce quality of life (QOL).  Furthermore, 
hospi[INVESTIGATOR_686204]. 
This can worsen BPSD and QOL. The National Alzheimer’s Plan 8 recognizes poor care and lack of caregiver 
support as two core areas in need of change. In hospi[INVESTIGATOR_6125], the re is a clear and convincing case for action through 
wide- scale adoption of effective, evidence-based systems-level change pro grams.  
2.1.1 DSM-H  
We developed the Dementia Symptom Management at Home Progra m (DSM-H) to assist home healthcare 
agencies to implement systems-level evidence-based practice change for PWD and their caregivers and found 
improved clinician abilities and patient outcomes 2,3. The DSM-H is a multi-component, evidence-based 
intervention. While much of the DSM-H carries over from home he althcare to hospi[INVESTIGATOR_6125], some of the program 
needed refinement for regulatory content, and clinical care content,  and addition of a home health aide (HHA) 
program. We have made these adaptions for hospi[INVESTIGATOR_686205]. The next logical step is to refine and test the program for effectiveness 
in a large pragmatic clinical trial. 
 
 
 
Study Number:  18-[ZIP_CODE]   Page 11 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  2.1.2 Provision of Hospi[INVESTIGATOR_686206] a care model that provides care for persons with serious illness w ith a life expectancy of less than 6 
months. Care can be provided across settings, though the major ity is provided in the home. The aim of hospi[INVESTIGATOR_686207], psychosocial, and spi[INVESTIGATOR_686208]. Hospi[INVESTIGATOR_686209] (IDT) that primarily includes nurses, social w orkers, spi[INVESTIGATOR_88858], physicians, 
advanced practice nurses, HHAs and volunteers. When a patient ele cts to receive hospi[INVESTIGATOR_686210], all of the care for their terminal condition is paid through hospi[INVESTIGATOR_6125], which receives a per-diem 
reimbursement from Medicare. Patients may not receive curative care  for their terminal condition. Hospi[INVESTIGATOR_686211], which are a mix of visits, usually weekly to 
biweekly, by [CONTACT_39137], social workers, spi[INVESTIGATOR_686212]. If symptoms become severe and require 
more intensive care, patients may receive either continuous care , which is care by a nurse in the home for the 
duration of the symptom crisis, or general inpatient care , which is short-term acute care services in a hospi[INVESTIGATOR_686213]. Should caregivers become burned out while  serving in hospi[INVESTIGATOR_6125], the hospi[INVESTIGATOR_686214]-term respi[INVESTIGATOR_220581] a nursing home to prevent permanent institutionalization. Continuous care 
can reduce hospi[INVESTIGATOR_207788], inpatient care, hospi[INVESTIGATOR_686215], however it is not always 
offered 4,5. Many PWD would prefer to die at home 6, and hospi[INVESTIGATOR_686216]. 
 
2.1.3 Hospi[INVESTIGATOR_686217] l eading to sub-
optimal outcomes 
 
16.5% of the over 1.[ADDRESS_930287] dementia as a secondary diagnosis 8, including 18.8% of cancer patients 9. However, many hospi[INVESTIGATOR_686218] a dearth of validated programs 10. Furthermore, the 
disseminated nature of the workforce makes developi[INVESTIGATOR_686219]. Clinicians also have a 
negative view of caring for PWD, and do not recognize that substantial  evidence exists showing differences in 
their care needs. 11-23. Family members of PWD thus report significant unmet needs related  to both symptom 
management and information about symptoms and the dying process, a lthough at lower rates than those not 
receiving hospi[INVESTIGATOR_6125] 24. Moreover, hospi[INVESTIGATOR_686220] 25. 
2.1.[ADDRESS_930288] of care for PWD receiving hospi[INVESTIGATOR_686221], but it has been reported 
that about 25% of care occurs at home and about 50% in nur sing homes 25.  However, the majority of extant 
research on hospi[INVESTIGATOR_686222] 26,27, 
current care provided 25,28- 31, and bereaved family perceptions of care 24,32- 34—not on interventions for improving 
quality.  
2.1.5 Behavioral and Psychological Symptoms of Dementia (BPSD) a re ineffectively treated 
BPSD are one of the most common and distressing symptoms in the PWD, occurring in over 40% of cases 35. 
BPSD include agitation, depression, delusions, hallucinations, personali ty changes and aggression. BPSD are 
associated with weight loss 36, functional disability 37, caregiver burden and burnout 38, nursing home admission 39, 
and progression of dementia 40. While multiple non-pharmacologic interventions are available and been found 
effective for the treatment of BPSD 41,42, they are often not used. Pharmacologic interventions are mostly 
ineffective in PWD unless they are targeting the underlying cause. For  instance, aggression and resistance to 
care are often treated by [CONTACT_238364], but antipsychotics do not treat t he cause of these BPSD and have 
significant side effects including sedation that lower the quality of life (QOL), as well as adverse events including 
stroke, and death, even with short-term use 43-45. There is a “black box” warning on use in PWD, indicating that 
antipsychotics should only be used in cases of last resort where the patien t is a danger to self or others, 
experiencing concerning psychosis, or in need of palliative sedatio n for terminal sedation where the patient is 
in the last days of life 46. In hospi[INVESTIGATOR_6125], antipsychotics are widely overused; 61% of PWD nationwide are  prescribed 
an antipsychotic 29.  
 
Study Number:  18-[ZIP_CODE]   Page 12 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930289] been recorded of the incidence of pa in in the community-dwelling PWD, the 
estimated incidence rate in older adults is over 50% [ADDRESS_930290] been found, despi[INVESTIGATOR_686223] (if not intensity) compared to other hospi[INVESTIGATOR_686224]. 
There have been conflicting reports regarding family perception of the quality of pain management 24,33,[ADDRESS_930291] common forms of pain 
PWD may present with such as osteoarthritis 58. Yet given hospi[INVESTIGATOR_6125]’s culture and initial organization around 
cancer care and relief of suffering, where opi[INVESTIGATOR_686225] d of care, PWD may receive opi[INVESTIGATOR_686226], including delirium, constipation, 
reduced cognition, nausea, and urinary retention 59. 
 
2.1.[ADDRESS_930292] significantly longer lengths of service tha n other populations receiving hospi[INVESTIGATOR_6125] 
(mean 105 days vs 69.5 overall, median 56 days vs 23 overall) [ADDRESS_930293] poor care quality. Because of the 
long length of service, if care quality improved, the benefit for PW D and their caregivers could be highly 
significant. If symptoms could be managed in the home through proactive ro utine or continuous care, the need 
for temporary respi[INVESTIGATOR_4594] (e.g. care in a nursing home due to  caregiver burnout), and inpatient care could be 
reduced. It could also help more PWD die in their home. This wo uld both lead to better patient- and family-
centered care and reduce costs. In one of the few studies looking at the breakdown of type of hospi[INVESTIGATOR_686227], 22% of PWD required continuous care and 25% required inpatient car e in the last 7 days of life 61. 
 
2.1.8 Caregivers are largely marginalized and ignored as part of the he althcare system 
 
Caregivers are largely marginalized and ignored as part of the healthca re system and not provided the training 
or assistance they need to successfully care for PWD 62. Informal caregivers, including family, friends, 
neighbors, and other acquaintances provide 83% of the care to  PWD living in the community 63, representing 
15.9 million people providing 18.1 billion hours of care 64. The primary tasks informal caregivers provide include 
activities of daily living (ADLs) and instrumental ADLs, medication m anagement and administration, adherence 
to treatment regimens, interfacing with the medical team, managing BPSD, finding support services, and hiring 
and managing paid caregivers 64. These tasks are known to cause caregivers stress, burden, and burn out and 
worsen their physical and mental health, including 2-3 times greater risk of developi[INVESTIGATOR_686228] 
(40%) 64. Furthermore, the biologic variable of sex plays an important role in informal caregiving, as caregiving 
is performed significantly more by [CONTACT_457621] (68%) 65, and they spend between 2-[ADDRESS_930294] cited study 
found a 2-3 fold higher risk in African-Americans and Hispanics co mpared to non-Hispanic whites (9.1%, 7.5%, 
2.9% respectively in the 65-74 age cohort with even higher disparitie s as age increases) 67. In addition to higher 
prevalence rates, African-American and Hispanic caregivers frequ ently believe cognitive impairment is a normal 
Study Number:  18-[ZIP_CODE]   Page 13 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930295] bee n implemented in the home, outside of 
hospi[INVESTIGATOR_686229].  For instance, the COPE program focuses on enhancing the PWD’s  functional 
capacity and improving caregiver skills in managing dementia. It incl udes [ADDRESS_930296] of BPSD, and the subsequent need f or emergent care, while increasing bereaved 
caregiver satisfaction.  
2.2 Name [CONTACT_686351]-H Hospi[INVESTIGATOR_686183], is an evidence-based practice quali ty improvement program that combines 
training, mentorship, workflow enhancements, assessment instruments, a BP SD treatment algorithm, and 
caregiver teaching pamphlets for clinical staff in hospi[INVESTIGATOR_441698] .  
Figure 1. DSM-H Hospi[INVESTIGATOR_686230]:  18-[ZIP_CODE]   Page 14 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19   
2.2.1 Champi[INVESTIGATOR_686231]-person didactic content, case 
studies, and role-playing simulated 
cases for members of the IDT at each 
agency. There are three core 
components of the champi[INVESTIGATOR_45371]: leadership, care of the PWD and caregiver, and communication within 
the team and with the PWD-caregiver dyad. The leadership content is modeled after the Hartford Institute for 
Geriatric Nursing’s highly successful NICHE program, which provides im plementation training on geriatric 
principles for acute care hospi[INVESTIGATOR_457578] 650 hospi[INVESTIGATOR_686232] 98. The leadership content also includes quality assurance and perfo rmance improvement (QAPI) 
methods for ensuring effective implementation. Dementia-specific conten t mirrors non-champi[INVESTIGATOR_45371] (see 
below) in more depth. The third component, dyadic person-cent ered team based care is based on three well 
validated programs, AHRQ TeamSTEPPS [ADDRESS_930297] problematic behaviors. Champi[INVESTIGATOR_686233] e in monthly troubleshooting calls with the 
coordinating center. Champi[INVESTIGATOR_686234] “hardwire” systems -level 
practice change. 
 
2.2.2 Non-champi[INVESTIGATOR_686235] (e.g. RNs, social workers, and spi[INVESTIGATOR_686236]) undergo five, one-hour modules of 
online interactive learning (CEUs provided) available over one mo nth.  This ensures completion of the modules 
without burdening staff or requiring them to take a lower patient w orkload, which could have significant fiscal 
impact on the agency and reduce the likelihood of involvement. The  content aligns with the champi[INVESTIGATOR_686237]. Module 1:  Defining and distinguishing types of dementia; assessing patients for de mentia ; 
basic non-pharmacologic and pharmacologic interventions for decline in PWD ; working with PWD to complete 
care tasks. Module 2: Assessing PWD for pain; non-pharmacologic and pharmacologic strategies for treating 
pain in the PWD. Module 3: Understanding, assessing and recogniz ing BPSD, acute delirium, and terminal 
delirium in PWD. Module 4: Non-pharmacologic and pharmacologic  interventions for managing BPSD and 
terminal delirium in PWD. Module 5: Dyadic team-based care concepts derived from AHRQ TeamSTEPPS, 
SBAR, and the patient-family centered antecedent-behavior-consequ ence model of problem solving. The 
nursing version includes more pharmacologic intervention informatio n and the IDT version includes basic 
pharmacologic information and more psychosocial care modalities.  
 
Hospi[INVESTIGATOR_686238], NPs, and PAs undergo a 1 h our online training module, focusing on the 
treatment algorithm; differentiating acute delirium, terminal delirium, an d chronic worsening of BPSD; care plans 
that will be activated by [CONTACT_686331], and their role in improving quality a s part of the IDT. 
 
2.2.[ADDRESS_930298] be provided to all HHA annually by [CONTACT_5035][INVESTIGATOR_6125]. HHA training for PWD described in D.3. is 4 
hours and includes 1) dementia basics; 2) Alzheimer’s and dem entia progression; 3) communication and 
providing effective care; 4) promoting wellness in a safe environm ent; 5) providing care to PWD with BPSD. 
The pi[INVESTIGATOR_686239]-led, but we received feedback fr om HHA and agencies that they are 
performing their continuing education online, so in the R61 phase w e will convert this program to a video/online 
program. 
2.2.[ADDRESS_930299] (EHR ) and workflow to allow for better Training Resources 
IDT Champi[INVESTIGATOR_5458] 
2 days, in person, dementia content +QAPI [CONTACT_375262];  
Systems- and team-level change agents  
HHA s 
4 hours, 
online, 
interactive Skilled IDT 
members 
5 hours, 
online, 
interactive Providers 
1 hour 
online, 
interactive Caregiver 
education 
pamphlets 
English & 
Spanish BPSD 
treatment 
algorithm Care plans 
& 
assessment 
instruments 
Study Number:  18-[ZIP_CODE]   Page 15 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  assessment of cognition, pain, and BPSD and are validated in bo th English and Spanish. The tools are 
reviewed in the training components. Instruments included are the  mini-cog 102 to screen for cognitive 
impairment, NPI-Q 103 for BPSD, the Cornell Scale for Depresion in Dementia 104 in moderate/severe 
dementia, the Geriatric Depression Scale-Short Form 105 for depression in mild dementia, the PAINAD 106 
for pain assessment in moderate/severe dementia, and the caregiver strain in dex 107. 
 
2.2.5 Interprofessional care plans  
 
Interprofessional care plans that guide overall care for PWD with spe cific plans for pain, 7 BPSD categories 
(aggression, apathy, depression, psychomotor agitation, psychosis, sexua l disinhibition, sleep disturbance), 
and terminal delirium, are available to clinicians. These care plan s provide assessment and management 
guidance to clinicians and are consistent with the information taught in  the online and champi[INVESTIGATOR_686240]. For instance, in PWD with sleep disturbance, care plans describe e vidence-based practices around 
implementing appropriate sleep hygiene and habits, stimulating patients  during the day through activities, and 
environmental changes to improve sleep quality. Each plan is associate d with tailored caregiver education 
pamphlets in English and generalized Latin American Spanish tha t can be reviewed on site electronically and 
provided on paper.  
2.2.6 BPSD treatment algorithm 
 
A BPSD treatment algorithm is provided that reinforces the educatio n, care plans, and caregiver education 
pamphlets. The algorithm takes clinicians through a differential proc ess to determine whether the event is likely 
acute delirium, terminal delirium, or a worsening of a chronic BPSD; and th en through potential triggers for the 
symptom, non-pharmacologic and pharmacologic approaches, and monito ring parameters. 
2.[ADDRESS_930300]. Brody’s National Palliative Care Research Center Career Development Awar d, [CONTACT_457691] 
developed the DSM-H. The development utilized the NIH ORBIT Mod el for Behavioral Intervention 
Development [ADDRESS_930301] educators (6 total educators)  at the study site were trained as “champi[INVESTIGATOR_5458]” 
and received 14 hours of in-person, case based interprofessional in struction over two days in dementia care; 
the remaining [ADDRESS_930302]. The 
survey incorporates three well-validated instruments for assessing clinician k nowledge and attitudes regarding 
pain 110, depression 111 and agitation 112 in PWD, with an investigator-derived set of four questions about 
confidence in treating each of these symptoms in PWD.  The survey had  an excellent internal consistency in 
HHC clinicians (Cronbach alpha=.94) and took an average of [ADDRESS_930303] improvement in 
knowledge (20.9%) and confidence (27.1%) in managing BPSD fro m baseline with additional gains in 
knowledge (14.8%) and confidence (36.1%) in managing depressio n and knowledge (5.9%) and confidence 
(26.5%) in managing pain (p<.0001) 2. Additionally, on the post-test evaluation, 97% of RNs and 10 0% of PTs 
and OTs stated the education was highly applicable to their work setting and  helped them care for patients.  
 
Study Number:  18-[ZIP_CODE]   Page 16 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930304] 60-day re-certification or discharge fro m HHC. Overall, during the study period 158 
PWD were seen by [CONTACT_457624] 174 by [CONTACT_457625] . Overall, patients were older, primarily spoke 
English or Spanish, were either Medicare or dual Medicare/Med icaid insured, and were admitted either from 
home or the acute care setting (See Appendix A). There were fewer  black/African American participants in the 
control, the only clinically significant difference (34.2% vs 51.7%; p=.000 2). Overall, we found in multivariate 
analysis that recognition of pain, depression, and behavioral symptom s, were all clinically and statistically 
significantly higher in the intervention group, and there were significa ntly increased odds of analgesics use 
(OR=2.01; p<.05) and decreased odds of antipsychotic use (OR-0.53; p<.05) in the intervention cohort 3. These 
results show the DSM-H has the potential to be improve patient care and the  QOL of PWD receiving HHC.  
 
2.3.[ADDRESS_930305] the efficacy of the DSM- H Hospi[INVESTIGATOR_686186] a behavioral pi[INVESTIGATOR_686241]. 
2.5 Potential Risks & Benefits 
Known Potential Risks 
This is a minimal risk study and that the agencies themselves are not eng aging in research but performing a 
performance improvement process and providing feedback, and the dat a we receive will be de-identified other 
than zip code and service dates so that we will not have minimal personall y identifiable information. 
 
The performance improvement program itself is inherently not risky ( minimal risk ) as it is an implementation 
of evidence-based practices. The primary risk to patients AND clinicia ns is loss of confidentiality. We minimize 
the risk by [CONTACT_457627] a secured fashion (see section 11 ). These vulnerable populations are 
included as the focus of the research is in improving the quality of care PW D receive, and the applicability of 
the DSM-H Hospi[INVESTIGATOR_686242] . The DSM-H could affect hospi[INVESTIGATOR_686243].  
 
As the potential risks are minimal and there are potential direct benefits to sub jects in the performance 
improvement cohort, including improved PWD QOL and symptom managem ent, the potential benefits of this 
study far outweigh the minimal risks to this study. The value in this study is t hat if feasibility, applicability and 
fidelity are found, a large-scale pragmatic trial will be performed in 25 h ospi[INVESTIGATOR_686244], thus leading to the disseminated to some of the over 4,000 active hospi[INVESTIGATOR_686245]:  18-[ZIP_CODE]   Page 17 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  agencies in the country to improve the quality of care in these settings and  QOL for hundreds of thousands of 
PWD and their caregivers. 
2.5.1 Known Potential Benefits 
 
Potential benefits to patients in the intervention includes improved qua lity of care and quality of life, including 
reduction in pain and BPSD, and reduced healthcare utilization, which could  lead to lower out of pocket costs.  
3 Objectives and Purpose 
3.1 Primary Objectives 
 
We developed the Dementia Symptom Management at Home Program (DSM- H) to assist home healthcare 
agencies to implement systems-level evidence-based practice change for P WD and their caregivers and 
found improved clinician abilities and patient outcomes. The DSM-H is a multi -component, evidence-based 
intervention. While much of the DSM-H carries over from home healthcare  to hospi[INVESTIGATOR_6125], some of the program 
needed refinement for regulatory content, and clinical care content, and  addition of a home health aide (HHA) 
program. We have made these adaptions for hospi[INVESTIGATOR_686246] t hem with strong clinician outcomes 
through two separate extramural awards. The next logical step is to refin e and test the program for 
effectiveness in a large pragmatic clinical trial. Through the 1-year R61 ph ase we will accomplish the 
following: 
 
Aim 1: Establish the infrastructure to implement a pragmatic cl inical trial of the DSM-H Hospi[INVESTIGATOR_686247]. We will establish a steering committee that will oversee all facets of the trial an d integrate the work of 
the following work groups: 1. Intervention refinement; 2. Intervention impl ementation; 3. Measurement; 4. 
Statistical methods; 5. Data management; 6. Stakeholders; 7. Human subjects  and data safety. 
 
Aim 2: Tailor the DSM-H Hospi[INVESTIGATOR_686248]-scale implementation in hospi[INVESTIGATOR_6125]. We will further refine the intervention focusing specifically  
on ensuring the following: 1. The content and training align specifically with hospi[INVESTIGATOR_686249]; 2. The content can be implemented in a wide-scale fa shion in hospi[INVESTIGATOR_441698]. 
 
Aim 3: Pi[INVESTIGATOR_686185]-H Hospi[INVESTIGATOR_686250] 2 hospi[INVESTIGATOR_686251]. 
 
4 Study Design and Endpoints 
4.1 Description of Study Design 
 
4.1.1 Aim 1: Establish the infrastructure to implement a pragmatic clinic al trial of the DSM- H 
Hospi[INVESTIGATOR_686183].  
 
We will establish a steering committee that will oversee all facets of the trial and integrate the work of the 
following work groups: 1. intervention refinement; 2. intervention imp lementation; 3. measurement; 4. statistical 
methods; 5. data management; 6. stakeholders; 7. human subjects and  data safety.  
Study Number:  18-[ZIP_CODE]   Page 19 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  including in PWD 
 
• Advisors: [CONTACT_686352], MD, Nationwide Medical Director for  Vitas Hospi[INVESTIGATOR_6125], and Associate 
Professor at University of Central [LOCATION_012], with expertise on care quali ty for PWD and their caregivers 
receiving hospi[INVESTIGATOR_3677] 
 
• [CONTACT_686353], JD, MPH, the Chief Strategy Officer of the Nationa l Partnership for Hospi[INVESTIGATOR_686252], an expert in health policy, innovation, and coalition leadership in ho spi[INVESTIGATOR_686253] (e.g. will no t have access to data, will not perform any 
recruitment). 
 
Work groups.  Each work group will be chaired by a member of the steering com mittee, and additional members 
will come from the core investigative team and partner agencies.  Each committee will be staffed by [CONTACT_686332]-doctoral associate during years 1-2, a nd then the project director in the remaining years. 
Groups will meet at the frequency necessary to complete the assigned charge throughout the R61 phase of the 
trial. 
4.1.2 Aim 2: Tailor the DSM-H Hospi[INVESTIGATOR_686254]-scale implementation in hospi[INVESTIGATOR_6125].  
We will further refine the intervention focusing specifically on ensuring  (1) that the content and training align 
specifically with hospi[INVESTIGATOR_686255] (2) that the content can be 
implemented in a wide-scale fashion in hospi[INVESTIGATOR_441698].  
 
Aligning existing content with the hospi[INVESTIGATOR_686256] . The intervention refinement and stakeholder work groups will 
refine the DSM-H Hospi[INVESTIGATOR_686183]. For existing content, the interve ntion refinement group will review and edit 
all materials. The stakeholder work group will provide an additional revi ew of this edition.  
 
Revising the HHA training as an online program.  The intervention refinement work group and our project staff 
will convert our HHA training program for PWD to an online format to allow for wider dissemination. This will 
include short, skills-based videos recorded at the NYU Rory Meyers College  of Nursing Simulation Center with 
standardized patients and HHA actors depi[INVESTIGATOR_686257]. The videos will be embedded within interactive learning m odules at a [ADDRESS_930306] and script  the simulation videos and interactive learning 
modules, and the stakeholder group will review them prior to produci ng. 
4.1.3 Aim 3: Pi[INVESTIGATOR_686185]-H Hospi[INVESTIGATOR_6125] E dition in [ADDRESS_930307] testing using 
the DSKA, which has established content and face validity and interna l consistency to measure the 
intervention’s effects on knowledge, confidence and attitudes 2. We will also perform a formative evaluation with 
completers regarding the applicability of the content through both quantit ative and qualitative survey feedback. 
Data will be collected in Qualtrics survey software. We will also conduct a shor t focus group with champi[INVESTIGATOR_686258]. For this focus grou p we will use field notes rather than 
recording, as the goal is not to perform a thorough scientific qualitative analysis but obtain feedback on what 
did and did not work in terms of applicability, relatability to the IDT and  implementability. The Focus groups and 
DSKA are being used for program evaluation and not research. 
 
Study Number:  18-[ZIP_CODE]   Page 20 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930308] systematic usability evaluation 
through anonymized screen recording, analyzing answers to embed ded questions within the modules, and a 
formative evaluation by [CONTACT_8333] (i.e., HHA who complete and do not complete the pro gram) 113. 
 
Testing the methods for collecting and merging patient-level data from the h ospi[INVESTIGATOR_287859]. We will not receive 
identified data. The measurement, data management, and human  subjects and data safety work groups will 
refine the specifications and protocol for securely transferring data fr om hospi[INVESTIGATOR_686259]. In this pi[INVESTIGATOR_2268], we will test collection of data from one month prior to implementation to one month after 
implementation. The data manager will clean and analyze the data descriptive ly and report back to these work 
groups and the statistical analysis work group for refinement of the analytic plan and to ensure that all the 
necessary elements are present and usable. 
 
Further refinement of intervention components and data collection. F ollowing initial pi[INVESTIGATOR_686260], implement ation, measurement, data management, 
statistical analysis, and data safety. The stakeholder work group will also review information on how the 
intervention affects stakeholders. Should further refinement of an y of these components be required the 
respective work groups will meet to make changes that will be sub mitted to the steering committee for 
integration.  
 
Second pi[INVESTIGATOR_21087]. Following integration of all necessary revisions, we will perfo rm a second pi[INVESTIGATOR_686261], CA. We chose this hospi[INVESTIGATOR_686262], has a smaller daily census, and serves a suburban are a with a high population of Spanish 
speakers. We will perform the same pi[INVESTIGATOR_686263] 4.1 .3.a, unless the work groups seek additional 
or different data points. 
 
4.1.4 Additional activities 
During the R61 phase, the work groups and steering committee wil l complete additional activities to prepare for 
the R33: 1. Update and finalize sites to participate in the trial with o ur partner agencies; 2. Update power 
analysis and adjust methodology accordingly; 3. Finalize data managemen t plan and infrastructure; 4. Finalize 
analytic plan; 5. Perform randomization; 6. Prepare timeline for in dividual sites and engage with the agencies 
in preparatory work. 7. Obtain data use agreements from each site; 8. S et up Data Safety Monitoring Board; 9. 
Obtain approval for R33 phase from IRB; 10. Register in clinicaltrials .gov; These activities will be carried out by 
[CONTACT_686333]. 
4.2 Study Endpoints 
4.2.1 Milestones  
Transition from the R61 (this protocol/IRB) to the R33 phase (sep arate second phase where new IRB 
application will be submitted) will be based on readiness for imple mentation as measured by [CONTACT_5870], 
applicability, and fidelity thresholds  achieved at the second pi[INVESTIGATOR_686264]. 
 
1) Feasibility. Milestone:  completion of all required education and training by [CONTACT_2669] 8 0% of eligible 
hospi[INVESTIGATOR_686265] 
 
2) Applicability . Milestone: post-implementation surveys indicating 80% of IDT members feel the 
program is applicable to their work and that they will implement chang es in their practice 
 
3) Fidelity.  Milestone: at least 75% of advanced dementia patients receiving ho me hospi[INVESTIGATOR_686266] 
1 care plan or assessment instrument utilized within the month following imp lementation. 
 
During this R61 year, we are also required by [CONTACT_686334] r the full R33 pragmatic clinical trial. 
Study Number:  18-[ZIP_CODE]   Page 21 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  5 Study Enrollment  
5.1 Inclusion Criteria  
 
CLINICIANS/AIDES; All English speaking interdisciplinary team (IDT) membe rs employed or contracted 
by [CONTACT_686335]-H online or champi[INVESTIGATOR_686267] 18 years of age will be 
eligible. 
 
PWD: All PWD who are newly admitted to a participating hospi[INVESTIGATOR_686268] 50 will be eligibl e.  
5.2 Exclusion Criteria  
 
None 
 
5.3 Strategies for Recruitment and Retention 
5.3.1 Clinicians 
The NYU study team will send an IRB approved recruitment email to all  eligible clinician subjects inviting them 
to the study. Upon entering the learning management system or ch ampi[INVESTIGATOR_686269], 
all eligible clinician subjects will be prompted as whether they wo uld like to participate (online for online training, 
and privately, in person by a NYU study staff member for champ ion training). For training, they may forgo this 
research and move straight to taking the training. All subjects com pleting online training will be consented 
electronically through electronic survey data collection using a st andardized consent approved by [CONTACT_686336] a waiver of documentation will be requested, as 
the act of taking the survey will serve as their consent.  
 
In the last question of the initial survey clinicians will be asked if they wa nt to complete an additional optional 
survey questionnaire. If they choose to participate they will be provid ed a link to complete these questions. 
Upon completion of this survey they will receive a $[ADDRESS_930309]. Those who  choose to complete this survey will 
be sent an addition follow up survey three months afterwards. At the end of this survey they will be asked if 
they would like to complete a telephone interview. If they say yes, they will be contact[CONTACT_686337]. 
They will receive an additional $[ADDRESS_930310] to complete the phone  interview. Total remuneration for the 
professional quality of life optional questions if both surveys and telephon e interview are completed is $100. 
 
For clinicians who complete online training, they will be prompted following completion of the training to 
complete a post-survey (DSKA or HHA assessment). They will be promp ted up to [ADDRESS_930311] the opportunity 
privately to notify us ahead of time that they do not want to participa te, or can notify us in person at any time 
throughout the champi[INVESTIGATOR_45371]. As the focus groups are for pro gram evaluation and not research purposes, 
we will not consent clinicians. 
5.3.2 Persons with Dementia 
 
We will seek to obtain de-identified data (with exception of dates of service and zip codes) of PWD who receive 
care from the hospi[INVESTIGATOR_686270] ( See milestone 
3 above ). We will seek a waiver of consent and authorization for this population a s NYU will not be performing 
Study Number:  18-[ZIP_CODE]   Page 22 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930312] between the PWD/s urrogate in this study would be 
to perform informed consent, and would not be practical given th e dispersed nature of the subject population 
and number of subjects we’d have to contact. In addition to IRB ap proval, a Data Use Agreem ent will be 
executed to obtain this data. 
 
5.[ADDRESS_930313]. An investigator 
may terminate participation in the study if: 
 
• The subject is unable to complete training or the individual leaves the hospi[INVESTIGATOR_686271]. 
5.5.2 Handling of Participant Withdrawals or Termination 
Given the minimal risk nature of this study, should individuals choose to withdraw from the study, we will not 
continue to follow- up or follow them in any form. 
 
6 Study Quality Improvement Program 
6.1 Study Behavioral or Social Quality Improvement Progra m 
 
The DSM- H Hospi[INVESTIGATOR_686272] 2.2  is a quality improvement program that has been 
adapted from and heavily based on the pre-existing DSM-H HHC  edition. The adaptation took into account 
regulatory and clinical team differences between the tw o. The original DSM-H was tested in several HHC agencies 
in [LOCATION_001] and the hospi[INVESTIGATOR_686273]’s  educational components were tested with a nationwide sample of ho spi[INVESTIGATOR_686274] . The DSM-H Hospi[INVESTIGATOR_686275] a multi-modal quality improvement program for improving the 
quality of care provided to PWD-informal caregiver dyads through hospi[INVESTIGATOR_6125] . The initial DSM-H home health 
edition training was initially created through participatory research with an interprofessional team of clinicians, 
and then refined through feedback from clinicians who complete d the training. It has been culturally tailored for 
use in diverse settings and tested with multiple minority communities in  [LOCATION_001], including multiple Hispanic 
groups and African-Americans and Caribbean blacks. This new hospi[INVESTIGATOR_686276]. The DSM- H Hospi[INVESTIGATOR_686277] a study intervention. We are solely in this study measuring the outcomes of the quality improvement 
program, however include the components of the program here so it is easier to understand the research 
protocol around the study of outcomes. 
6.1.1 Procedures for Training Quality Improvement Teams and Monitoring Fidelit y 
Because there are multiple care teams receiving the performance im provement program , and we need to 
understand how well the program is implemented in order to assess the research outcomes, we will measure 
Study Number:  18-[ZIP_CODE]   Page 23 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  fidelity of implementation (e.g. clinician exposure to the performa nce improvement program) as well as 
differences across control and performance improvement teams throu gh assessing registered nurse, physical 
and occupational therapi[INVESTIGATOR_457587], attitudes and confidence using [CONTACT_457691]’s previously validated 
dementia symptom knowledge and attitudes survey at baseline, 3 mo nths, and 1 year 2, and through measuring 
the number of care plans initiated, caregiver teaching sheets provide d to caregivers, and assessment 
instruments used at each site throughout the trial.  
 
7 Study Procedures and Schedule 
7.1 Study Procedures/Evaluations 
7.1.1 Study Specific Procedures 
[IP_ADDRESS] Clinician Knowledge, Confidence, Attitudes 
We will implement the DSM-H Hospi[INVESTIGATOR_686278], then m ake iterative changes for usability and 
applicability based on feedback from our stakeholder workgroup an d the MJHS hospi[INVESTIGATOR_686279], and 
implement at Providence Trinity Hospi[INVESTIGATOR_6125]. 
 
To assess knowledge of the clinicians, the DSKA (skilled clinicians) or  HHA assessment (hospi[INVESTIGATOR_686280]) will be 
collected prior to and post online training via Qualtrics survey. It  takes approximately 15 minutes to complete 
the former and 10 minutes the latter. The DSKA includes ba seline demographics (first survey only for an 
individual) and [ADDRESS_930314] two  years and it has strong internal consistency 
and validity.  
[IP_ADDRESS] Optional Professional Quality of Life 
We will implement the professional quality of life survey at pi[INVESTIGATOR_365883] 2 to assess professional quality of life of the 
clinicians before and after DSM-H hospi[INVESTIGATOR_686281]. It takes approxi mately 10 minutes to complete the surveys. 
The survey instruments include the professional quality of life ( ProQOL-5), which is a [ADDRESS_930315] 30 days. The scale starts at one indicating 
never and goes to five indicating very often. It measures professional q uality of life on three subscales including 
compassion satisfaction, burnout and secondary traumatic stress. Higher  scores on the burnout and secondary 
traumatic stress indicate higher risk for burnout and higher seconda ry traumatic stress, respectively. Higher 
scores on the compassion satisfaction scale indicate greater satisfaction in your ability to be an effective 
caregiver at your job. 114 A 9-item Well-being Index (WBI) will be used to identify U.S. workers in distress and 
stratify quality of life. The WBI is a successful screening tool to identif y distress and identify those with high 
well-being among nurses 115,116  and among a variety of workers. 115 Supplemental questions asked will be taken 
from the National Sample Survey of Registered Nurses question num bers: 36, 66, 67. The last question 
included is a retention question that asks : “Do you plan to be with your employer one year from now? ” Yes or 
No. 
[IP_ADDRESS] Applicability to the setting 
 
In addition to asking clinicians and hospi[INVESTIGATOR_686282], confidence and attitudes, we will also 
ask them about the applicability of the program through a serie s of questions via the online survey (see 
questions under other materials). 
Study Number:  18-[ZIP_CODE]   Page 24 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19   
We will also perform a focus group with all champi[INVESTIGATOR_686283]. The focus group will be held 
in the same room where the champi[INVESTIGATOR_686284] 
20 minutes to complete. The focus group will ask three open end ed questions about the champi[INVESTIGATOR_686182], 
with follow-up questions based on response. These questions are: wha t did you feel were the best parts of the 
champi[INVESTIGATOR_686285]; what did you feel were the parts you  liked least about the champi[INVESTIGATOR_686286]; how do you think it will help you change the practice of clinicians in you r agency; what would you change 
about the champi[INVESTIGATOR_686182]?  
 
7.1.[ADDRESS_930316] be en initiated, and types and frequency of 
symptoms, and pharmacologic and non-pharmacologic interventions utilized . 
7.2.5 Withdrawal/Early Termination Visit 
Clinician subjects can withdraw from the study at any time, and wil l not have to complete the assessment 
instruments, though they may be required by [CONTACT_5035][INVESTIGATOR_686287]. 
Study Number:  18-[ZIP_CODE]   Page 25 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  8 Assessment of Safety 
8.1 Staff (Clinicians) 
There is minimal risk to the healthcare staff as the content is not sensitive in nature and the surveys do not 
significantly relate to measures on which staff are measured for jo b accountability. The greatest risk to staff is 
the loss of confidentiality. We will not share any data collected back to th e agency. For reporting purposes in 
conference proceedings, abstracts and manuscripts, data will be ag gregated to ensure lack of identifiability to 
the staff level.  
 
8.[ADDRESS_930317] . 
 
10 Statistical Consideratio ns 
10.1 Statistical and Analytical Plans (SAP) 
A formal SAP will not be completed for this study. 
 
10.[ADDRESS_930318] achieve in order to 
proceed to the R33 phase of the grant (to be submitted under separ ate IRB): 
 
1. Feasibility. Milestone:  completion of all required education and training by [CONTACT_2669] 8 0% of eligible 
hospi[INVESTIGATOR_686265] 
 
2. Applicability . Milestone: post-implementation surveys indicating 80% of IDT members feel the 
program is applicable to their work and that they will implement chang es in their practice 
 
Study Number:  18-[ZIP_CODE]   Page 26 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  3. Fidelity.  Milestone: at least 75% of advanced dementia patients receiving hom e hospi[INVESTIGATOR_686266] 
1 care plan or assessment instrument utilized within the month following imp lementation. 
10.3 Analysis Datasets 
We will maintain separate data sets nested by [CONTACT_686338], ho spi[INVESTIGATOR_686280], and PWD. 
 
10.4 Description of Statistical Methods 
10.4.1 General Approach 
 
Data Analysis will be performed using SAS 9.4 117. We will perform basic descriptive tests to examine baseline 
characteristics of the patient populations and clinician populations. We wil l perform paired t-tests to examine 
differences in knowledge, confidence and attitudes from baseline, as well as tests of validity and reliability. 
10.4.2 Adherence and Retention Analyses 
We will perform sensitivity analyses to examine whether there are difference s in those who are retained in the 
study vs those who withdraw/are terminated. As this is a cluster rand omized trial, adherence is related to the 
quality improvement program implementation at the care team level a nd therefore falls under fidelity monitoring. 
We will examine differences in DSKA scores submitted by [CONTACT_2360][INVESTIGATOR_686288] t-tests and repe ated measures ANOVA. 
10.5 Sample Size 
 
This study will utilize a convenience sample for both PWD and clinicians base d on those available and eligible 
at the time of implementation as this is a R61 pi[INVESTIGATOR_686289]. 
 
11 Source Documents and Access to Source Data/Documents 
 
Source data is all information, original records of clinical findings, obs ervations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial.  S ource data are contained in source 
documents.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical and 
office charts, laboratory notes, memoranda, subjects’ diaries or eval uation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_686290], microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, 
and records kept at the pharmacy, at the laboratories, and at me dico-technical departments involved in the 
clinical trial. It is acceptable to use CRFs as source documents.  If this is the case, it should be stated in this 
section what data will be collected on CRFs and what data will be collected fro m other sources. 
 
All clinician data, which has no PHI, will be collected using Qualtr ics, which is hosted by [CONTACT_686339] . 
All de-identified data sets (other than zip codes and dates of servi ce) will be maintained on a secure MCIT 
managed research drive. 
 
Access to study records will be limited to IRB-approved members of the  study team. The investigator will permit 
study-related monitoring, audits, and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory bodies, 
and University compliance and quality assurance groups of all stud y related documents (e.g. source 
documents, regulatory documents, data collection instruments, stu dy data etc.).  The investigator will ensure 
the capability for inspections of applicable study-related facilities (e.g. ph armacy, diagnostic laboratory, etc.). 
 
Participation as an investigator in this study implies acceptance of p otential inspection by [CONTACT_686340] s. 
Study Number:  18-[ZIP_CODE]   Page 27 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  12 Quality Assurance and Quality Control 
 
QC procedures will be implemented beginning with the data entry system and d ata QC checks that will be run 
on the database will be generated. Any missing data or data anomalies wi ll be communicated to the site(s) for 
clarification/resolution. 
 
The PI [INVESTIGATOR_686291] R61 pi[INVESTIGATOR_686292] a re generated, documented (recorded), 
and reported in compliance with the protocol, and GCP in coordination wi th the study statistician. 
 
NYU will provide direct access to all source data/documents, and repo rts for the purpose of monitoring and 
auditing by [CONTACT_456], and inspection by [CONTACT_686341] s. 
 
13 Ethics/Protection of Human Subjects 
13.[ADDRESS_930319] 
 
The investigator will ensure that this study is conducted in full conformity with R egulations for the Protection of 
Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CF R Part 56, and/or the ICH E6. 
 
13.[ADDRESS_930320] 
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to 
the IRB for review and approval. Approval of both the protocol an d the consent form must be obtained before 
any participant is enrolled. Any amendment to the protocol will re quire review and approval by [CONTACT_142286]. All changes to the cons ent form will be IRB approved; a 
determination will be made regarding whether previously consented particip ants need to be re-consented. 
 
The following consent materials are submitted with this protocol: 
 
Study Information Survey Header-Clinician 
Application for Waiver of Documentation of Informed Consent-Clinician 
Application for Waiver of Authorization and Informed Consent-PWD 
13.3 Informed Consent Process 
13.3.1 Consent/Assent-PWD  
 
Because we are only obtaining data that is routinely collected by [CONTACT_686342][INVESTIGATOR_686293], we will be seeking waiver of authorization and informed conse nt. Therefore, there will be no 
recruitment or retention per se as we will only be obtaining de-identified data other than dates of service and 
zip codes from PWD and caregivers who have received care at a particip ating hospi[INVESTIGATOR_6125].  
 
13.3.[ADDRESS_930321]  survey that is minimal risk in nature and 
obtaining signed consent would not be feasible. 
 
Study Number:  18-[ZIP_CODE]   Page 28 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930322] use your NYU login credential and 2 factor 
authentication to access through a secure portal. Once data is collected and bein g prepared for analysis, it will 
be downloaded into a NYU Box folder owned by [CONTACT_978] [INVESTIGATOR_686294]. NYU Box is controlled by [CONTACT_686343] 2 factor 
authentication. It is approved by [CONTACT_686344] d Campus IT for maintaining sensitive 
information, though we are not collecting PHI. Data will be collecte d through the Qualtrics survey by [CONTACT_686345] a personal or agency owned device but entered data are not retained on the device. Data collected 
by [CONTACT_686346]- to-end.  
13.4.3 Research Use of Stored Human Samples, Specimens, or Data 
• Intended Use: Data collected under this protocol may be used to study d ementia or hospi[INVESTIGATOR_3677] 
• Storage: Only approved investigators will have access to the study data. 
 
13.[ADDRESS_930323]. 
 
Data collection is the responsibility of the study staff at the site unde r the supervision of the site PI. The 
investigator is responsible for ensuring the accuracy, completeness, le gibility, and timeliness of the data 
reported. 
 
All source documents should be completed in a neat, legible manner to e nsure accurate interpretation of data. 
Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out 
the original entry with a single line, and initial and date the change . DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL. 
 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for recording 
data for each participant enrolled in the study. Data reported in the eCRF derived from source documents 
Study Number:  18-[ZIP_CODE]   Page 29 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  should be consistent with the source documents or the discrepancies  should be explained and captured in a 
progress note and maintained in the participant’s official electronic study record.  
 
Clinical data (including AEs, concomitant medications, and expected a dverse reactions data) and clinical 
laboratory data will be entered into RedCap, a [ADDRESS_930324] protection 
and internal quality checks, such as automatic range checks, to identify d ata that appear inconsistent, 
incomplete, or inaccurate. Clinical data will be entered directly from the sou rce documents. 
 
14.2 Study Records Retention 
Study documents will be retained for the longer of 3 years after close-out, 5 years after final 
reporting/publication .  
14.3 Protocol Deviations 
 
A protocol deviation is any noncompliance with the clinical trial pro tocol, GCP, or Manual of Procedures (MOP) 
requirements. The noncompliance may be either on the part of the  participant, the investigator, or the study site 
staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3433] e site and implemented promptly. 
 
These practices are consistent with ICH E6: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality Assurance and Quality Control, section 5.1.1 
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
 
It is the responsibility of the site PI/study staff to use continuous vigilan ce to identify and report deviations within 
[ADDRESS_930325] be reported to the local IRB per their guidelin es. The site PI/study staff is responsible 
for knowing and adhering to their IRB requirements. Further d etails about the handling of protocol deviations 
will be included in the MOP. 
 
14.4 Publication and Data Sharing Policy 
 
 
The International Committee of Medical Journal Editors (ICMJE) me mber journals have adopted a clinical trials 
registration policy as a condition for publication. The ICMJE defines a cli nical trial as any research project that 
prospectively assigns human subjects to intervention or concurrent c omparison or control groups to study the 
cause-and-effect relationship between a medical intervention and a h ealth outcome. Medical interventions 
include drugs, surgical procedures, devices, behavioral treatments,  process- of-care changes, and the like. 
Health outcomes include any biomedical or health-related measure s obtained in patients or participants, 
including pharmacokinetic measures and adverse events. The ICMJE p olicy, and the Section [ADDRESS_930326] of 2007, requires that all clinical t rials be registered in a public trials 
registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_104429] L ibrary of Medicine. Other biomedical 
journals are considering adopting similar policies. For interventio nal clinical trials performed under NIH IC grants 
and cooperative agreements, it is the grantee’s responsibility to r egister the trial in an acceptable registry, so 
the research results may be considered for publication in ICMJE m ember journals. The ICMJE does not review 
specific studies to determine whether registration is necessary; instead,  the committee recommends that 
researchers who have questions about the need to register err on the side of registration or consult the editorial 
office of the journal in which they wish to publish. 
Study Number:  18-[ZIP_CODE]   Page 30 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.[ADDRESS_930327] experts 
at other universities, two hospi[INVESTIGATOR_686295] ([CONTACT_686354], MD of Vitas Hospi[INVESTIGATOR_686296]. 
Molly Gurian, JD, MPH of the National Partnership for Hospi[INVESTIGATOR_686297]) and a caregiver stakeholder 
representative (TBN) . The Steering Committee will govern the conduct of the study. 
 
[ADDRESS_930328] with this study (patent owne rship, royalties, or financial gain 
greater than the minimum allowable by [CONTACT_1385], etc.) m ust have the conflict reviewed by [CONTACT_46205] (CIMU) with a Committee-san ctioned conflict management plan 
that has been reviewed and approved by [CONTACT_686347]. All NYULMC 
investigators will follow the applicable conflict of interest policies. 
  
Study Number:  18-[ZIP_CODE]   Page 31 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  18 References 
1. D'Astous V, Abrams R, Vandrevala T, Samsi K, Manthorpe J. Gaps in u nderstanding the experiences 
of homecare workers providing care for people with dementia up to the e nd of life: A systematic 
review. Dementia (London, England). 2017:1471301217699354. 
2. Brody AA, Guan C, Cortes T, Galvin JE. Development and testing of the De mentia Symptom 
Management at Home (DSM-H) program: An interprofessional home hea lth care intervention to 
improve the quality of life for persons with dementia and their caregiver s. Geriatr Nurs. 
2016;37(3):200-206. 
3. Brody AA, Cortes T, Galvin JE. Helpi[INVESTIGATOR_686298] w ith dementia receiving home 
healthcare: A site-controlled trial of the Dementia Symptom Management at Home Program. In 
Review. 
4. Casarett D, Harrold J, Harris PS, et al. Does Continuous Hospi[INVESTIGATOR_686299]? J Pain Symptom Manage. 2015;50(3):297-304. 
5. Wang SY, Aldridge MD, Canavan M, Cherlin E, Bradley E. Continuous Ho me Care Reduces Hospi[INVESTIGATOR_686300]. J Pain Symptom Manage. 
2016;52(6):813-821. 
6. Badrakalimuthu V, Barclay S. Do people with dementia die at their pre ferred location of death? A 
systematic literature review and narrative synthesis. Age Ageing. 2014;43(1):13-19. 
7. National Hospi[INVESTIGATOR_686301]. Facts and Figures. Hospi[INVESTIGATOR_602333]. 
Alexandria, VA2017. 
8. Burton CZ, Twamley EW, Lee LC, et al. Undetected cognitive impairment a nd decision-making 
capacity in patients receiving hospi[INVESTIGATOR_3677]. Am J Geriatr Psychiatry. 2012;20(4):306- 316. 
9. Legler A, Bradley EH, Carlson MD. The effect of comorbidity burden o n health care utilization for 
patients with cancer using hospi[INVESTIGATOR_6125]. J Palliat Med. 2011;14(6):751- 756. 
10. Goodman C, Evans C, Wilcock J, et al. End of life care for community dwellin g older people with 
dementia: an integrated review. Int J Geriatr Psychiatry. 2010;25(4):329- 337. 
11. Herr KA, Garand L. Assessment and measurement of pain in older adu lts. Clinics in Geriatric 
Medicine. 2001;17(3):457-478. 
12. Van Someren EJW. Circadian and sleep disturbances in the elderly. Exp Gerontol. 2000;35(9-
10):1229-1237. 
13. McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV. Treatment of sleep disturbance in 
Alzheimer's disease. Sleep Medicine Reviews. 2000;4(6):603-628. 
14. Montorio I, Izal M. The Geriatric Depression Scale: A Review of Its Developme nt and Utility. Int 
Psychogeriatr. 2005;8(01):103- 112. 
15. Narici MV, Maganaris CN, Reeves ND, Capodaglio P. EFFECT OF AGING ON HU MAN MUSCLE 
ARCHITECTURE. J Appl Physiol. 2003:4332003. 
16. Gibson SJ, Farrell M. A Review of Age Differences in the Neurophysiology of Nociception and the 
Perceptual Experience of Pain. The Clinical Journal of Pain. 2004;20(4):227. 
17. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age-and G ender-Related 
Ventricular-Vascular Stiffening A Community-Based Study. In . Vol 112: Am Heart Assoc; 2005:2254-
2262.  
18. Craik FIM, McDowd JM. Age Differences in Recall and Recognition. Age. 2007;278:739. 
19. Wenzel LB, Fairclough DL, Brady MJ, et al. Age-related differences in the  quality of life of breast 
carcinoma patients after treatment. Cancer. 1999;86(9):1768-1774. 
20. Gibson SJ, Helme RD. Age-related differences in pain perception and repo rt. Clinics in Geriatric 
Medicine. 2001;17(3):433-456. 
21. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Upd ating the Beers Criteria for 
Potentially Inappropriate Medication Use in Older Adults Results of a US Consensus Pa nel of 
Experts. In . Vol 163: Am Med Assoc; 2003:2716-2724. 
22. Rosenstock J. Management of Type 2 Diabetes Mellitus in the Elderly: S pecial Considerations. Drugs 
Aging. 2001;18(1):31. 
23. Stoltz P, Uden G, Willman A. Support for family carers who care for an  elderly person at home- a 
systematic literature review. Scand J Caring Sci. 2004;18(2):111-119. 
24. Teno JM, Gozalo PL, Lee IC, et al. Does hospi[INVESTIGATOR_686302]? J Am Geriatr Soc. 2011;59(8):1531-1536. 
Study Number:  18-[ZIP_CODE]   Page 32 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  25. Albrecht JS, Grub er-Baldini AL, Fromme EK, McGregor JC, Lee DS, Furuno JP. Quality of hosp ice 
care for individuals with dementia. J Am Geriatr Soc. 2013;61(7):1060-1065. 
26. Han B, Tiggle RB, Remsburg RE. Characteristics of patients receiving hospi[INVESTIGATOR_6125] c are at home versus 
in nursing homes: results from the National Home and Hospi[INVESTIGATOR_686303] t he National Nursing 
Home Survey. Am J Hosp Palliat Care. 2007;24(6):479-486. 
27. Unroe KT, Sachs GA, Dennis ME, et al. Hospi[INVESTIGATOR_686304]-nursing home 
patients. J Gen Intern Med. 2015;30(2):193-198. 
28. Shega JW, Hougham GW, Stocking CB, Cox-Hayley D, Sachs GA. Patients dyi ng with dementia: 
experience at the end of life and impact of hospi[INVESTIGATOR_3677]. J Pain Symptom Manage. 2008;35(5):499-
507. 
29. Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospi[INVESTIGATOR_413222]. Am J Hosp Palliat Care. 2014;31(2):126-131. 
30. De Vleminck A, Morrison RS, Meier DE, Aldridge MD. Hospi[INVESTIGATOR_686305] W ith Dementia in the 
[LOCATION_002]: A Longitudinal Cohort Study. J Am Med Dir Assoc. 2017. 
31. Dwyer LL, Lau DT, Shega JW. Medications That Older Adults in Hospi[INVESTIGATOR_686306], 2007. J Am Geriatr Soc. 2015;63(11):2282-2289. 
32. Wladkowski SP. Live Discharge from Hospi[INVESTIGATOR_686307]. J 
Soc Work End Life Palliat Care. 2016;12(1-2):47- 62. 
33. Tarter R, Demiris G, Pi[INVESTIGATOR_2531] K, Washington K, Parker Oliver D. Pain in Hospi[INVESTIGATOR_686308]: 
The Informal Caregiver Experience. Am J Alzheimers Dis Other Demen. 2016;31(6):524-529. 
34. Wladkowski SP. Dementia Caregivers and Live Discharge from Hospi[INVESTIGATOR_6125]: What H appens When 
Hospi[INVESTIGATOR_686309]? J Gerontol Soc Work. 2017;60(2):138-154. 
35. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevale nce of neuropsychiatric 
symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170- 177. 
36. White HK, McConnell ES, Bales CW, Kuchibhatla M. A 6-month observational stu dy of the 
relationship between weight loss and behavioral symptoms in institutionalized Alzheime r's disease 
subjects. Journal of the American Medical Directors Association. 2004;5(2):89-97. 
37. Peters KR, Rockwood K, Black SE, et al. Neuropsychiatric symptom clusters a nd functional disability 
in cognitively-impaired-not-demented individuals. The American journal of geriatric psychiatry : official 
journal of the American Association for Geriatric Psychiatry. 2008;16(2):136-144. 
38. Ballard C, Lowery K, Powell I, O'Brien J, James I. Impact of Behavio ral and Psychological Symptoms 
of Dementia on Caregivers. Int Psychogeriatr. 2000;12(SupplementS1):93-105. 
39. Gaugler JE, Wall MM, Kane RL, et al. The effects of incident and persist ent behavioral problems on 
change in caregiver burden and nursing home admission of persons w ith dementia. Med Care. 
2010;48(10):875-883. 
40. Chan WC, Lam LC, Tam CW, et al. Neuropsychiatric symptoms are associated wi th increased risks 
of progression to dementia: a 2-year prospective study of 321 Chinese  older persons with mild 
cognitive impairment. Age Ageing. 2011;40(1):30- 35. 
41. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for  agitation in dementia: a 
systematic review and meta-analysis. Aging & Mental Health. 2009;13(4):512- 520. 
42. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symp toms of severe 
agitation and aggression: consensus statement on treatment options, clinica l trials methodology, and 
policy. The Journal of clinical psychiatry. 2008;69(6):889- 898. 
43. Schneider LS, Dagerman KS, Insel P. Risk of death with atypi[INVESTIGATOR_67128] d rug treatment for 
dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934- 1943.  
44. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short -term serious events in 
older adults with dementia. Arch Intern Med. 2008;168(10):1090-1096. 
45. Steinberg M, Lyketsos CG. Atypi[INVESTIGATOR_600591]: ma naging safety 
concerns. Am J Psychiatry. 2012;169(9):900- 906. 
46. Beller EM, van Driel ML, McGregor L, Truong S, Mitchell G. Palliative phar macological sedation for 
terminally ill adults. Cochrane Database Syst Rev. 2015;1:CD010206. 
47. Sha MC, Callahan CM, Counsell SR, Westmoreland GR, Stump TE, Kroenke  K. Physical symptoms 
as a predictor of health care use and mortality among older adults. The American Journal of 
Medicine. 2005;118(3):301-306. 
48. Pi[INVESTIGATOR_6259], Strandberg TE, Tilvis RS. Management of Nonmalignant P ain in Home-Dwelling Older 
People: A Population-Based Survey. Geriatrics. 2002;50(11):1861-1865. 
Study Number:  18-[ZIP_CODE]   Page 33 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  49. Hanlon JT, Landerman LR, Wall WE, et al. Is Medication Use by [CONTACT_328619] -dwelling Elderly People 
Influenced by [CONTACT_457679]? Age Ageing. 1996;25(3):190- 196. 
50. Yong HH, Gibson SJ, de L. Horne DJ, Helme RD. Development of a Pain Attitudes Questionnaire to 
Assess Stoicism and Cautiousness for Possible Age Differences. Journals of Gerontology Series B: 
Psychological Sciences and Social Sciences. 2001;56(5):279-284. 
51. Monroe TB, Gibson SJ, Bruehl SP, et al. Contact [CONTACT_686348] r's disease: a cross-
sectional study. BMC Med. 2016;14:74. 
52. American Geriatrics Society. The management of persistent pain in old er persons. AGS panel on 
persistent pain in older persons. J Am Geriatr Soc. 2002;50(s6):205- 224. 
53. Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and o pi[INVESTIGATOR_686310]. J Gerontol A Biol Sci Med Sci. 2003;58(1):76- 81. 
54. Morrison RS, Magaziner J, McLaughlin MA, et al. The impact of post-o perative pain on outcomes 
following hip fracture. Pain. 2003;103(3):303- 311. 
55. Daltroy LH, Larson MG, Eaton HM, Phillips CB, Liang MH. Discrepancies b etween self-reported and 
observed physical function in the elderly: the influence of response shift an d other factors. Soc Sci 
Med. 1999;48(11):1549-1561. 
56. Foley SJ, Lord SR, Srikanth V, Cooley H, Jones G. Falls risk is associated  with pain and dysfunction 
but not radiographic osteoarthritis in older adults: Tasmanian Older Adult C ohort study. Osteoarthritis 
Cartilage. 2006;14(6):533-539. 
57. Kayser-Jones JS, Kris AE, Miaskowski CA, Lyons WL, Paul SM. Hospi[INVESTIGATOR_686311]: 
does it contribute to higher quality pain management? Gerontologist. 2006;46(3):325- 333. 
58. Krebs EE, Gravely A, Nugent S, et al. Effect of Opi[INVESTIGATOR_686312]-Related 
Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: Th e SPACE 
Randomized Clinical Trial. JAMA. 2018;319(9):872- 882. 
59. Chau DL, Walker V, Pai L, Cho LM. Opi[INVESTIGATOR_357206]: use and side effe cts. Clinical interventions in 
aging. 2008;3(2):273- 278. 
60. National Hospi[INVESTIGATOR_686313]. Facts and Figures: Hospi[INVESTIGATOR_602333]. 
Alexandria, VA2017. 
61. Miller SC, Kinzbrunner B, Pettit P, Williams JR. How does the timing of ho spi[INVESTIGATOR_686314]? J Am Geriatr Soc. 2003;51(6):798-806. 
62. National Academies of Sciences Engineering and Medicine. Families Caring for an Aging America. 
Washington, D.C.: National Academies of Sciences Engineering and Medicine; 2016. 
63. Friedman EM, Shih RA, Langa KM, Hurd MD. US Prevalence And Predictor s Of Informal Caregiving 
For Dementia. Health Aff (Millwood). 2015;34(10):1637-1641. 
64. Alzheimer's Association. 2016 Alzheimer's Disease Facts and Figures. Chicago, IL: Alzheimer's 
Association;2016. 
65. Kim H, Chang M, Rose K, Kim S. Predictors of caregiver burden in careg ivers of individuals with 
dementia. J Adv Nurs. 2012;68(4):846- 855. 
66. Chin AL, Negash S, Hamilton R. Diversity and disparity in dementia: the impact o f ethnoracial 
differences in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25(3):187-195. 
67. Gurland BJ, Wilder DE, Lantigua R, et al. Rates of dementia in three ethn oracial groups. Int J Geriatr 
Psychiatry. 1999;14(6):481- 493. 
68. Mahoney DF, Cloutterbuck J, Neary S, Zhan L. African American, Chinese , and Latino Family 
Caregivers' Impressions of the Onset and Diagnosis of Dementia: Cross- Cultural Similarities and 
Differences. The Gerontologist. 2005;45(6):783- 792. 
69. Livney MG, Clark CM, Karlawish JH, et al. Ethnoracial differences in the  clinical characteristics of 
Alzheimer's disease at initial presentation at an urban Alzheimer's disease  center. Am J Geriatr 
Psychiatry. 2011;19(5):430- 439. 
70. Chen JC, Borson S, Scanlan JM. Stage-specific prevalence of behavioral symp toms in Alzheimer's 
disease in a multi-ethnic community sample. Am J Geriatr Psychiatry. 2000;8(2):123-133. 
71. Mausbach BT, Coon DW, Depp C, et al. Ethnicity and time to institutionalization  of dementia patients: 
a comparison of Latina and Caucasian female family caregivers. J Am Geriatr Soc. 2004;52(7):1077-
1084.  
72. Scott WK, Edwards KB, Davis DR, Cornman CB, Macera CA. Risk of institu tionalization among 
community long-term care clients with dementia. Gerontologist. 1997;37(1):46-51. 
Study Number:  18-[ZIP_CODE]   Page 34 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  73. Oud L. Predictors of Transition to Hospi[INVESTIGATOR_686315] a Diagnosis of 
Dementia in [LOCATION_007]: A Population-Based Study. J Clin Med Res. 2017;9(1):23- 29. 
74. Brody AA, Galvin JE. A review of interprofessional dissemination and ed ucation interventions for 
recognizing and managing dementia. Gerontol Geriatr Educ. 2013;34(3):225-256. 
75. Chodosh J, Berry E, Lee M, et al. Effect of a dementia care managem ent intervention on primary care 
provider knowledge, attitudes, and perceptions of quality of care. J Am Geriatr Soc. 2006;54(2):311-
317. 
76. Ellis IK, Philip T. Improving the skills of rural and remote generalists to manage mental health 
emergencies. Rural Remote Health. 2010;10(3):1503. 
77. Gallagher M. Evaluating a protocol to train hospi[INVESTIGATOR_686316] g individualized music. Int J 
Palliat Nurs. 2011;17(4):195- 201. 
78. Galvin JE, Kuntemeier B, Al-Hammadi N, Germino J, Murphy-White M, M cGillick J. "Dementia-
friendly Hospi[INVESTIGATOR_600]: Care not Crisis": An Educational Program Designed to Imp rove the Care of the 
Hospi[INVESTIGATOR_457611]. Alzheimer Dis Assoc Disord. 2010. 
79. McAiney CA, Stolee P, Hillier LM, et al. Evaluation of the sustained implem entation of a mental health 
learning initiative in long-term care. International psychogeriatrics / IPA. 2007;19(5):842-858. 
80. Meuser TM, Carr DB, Berg-Weger M, Niewoehner P, Morris JC. Drivin g and dementia in older adults: 
Implementation and evaluation of a continuing education project. The Gerontologist. 2006;46(5):680-
687. 
81. Barton C, Miller B, Yaffe K. Improved evaluation and management of co gnitive impairment: results of 
a comprehensive intervention in long-term care. Journal of the American Medical Directors 
Association. 2006;7(2):84-89. 
82. Cherry DL, Hahn C, Vickrey BG. Educating primary care physicians in the m anagement of 
Alzheimer's disease: using practice guidelines to set quality benchmarks.  International 
psychogeriatrics / IPA. 2009;[ADDRESS_930329] 1:S44-52. 
83. Chrzescijanski D, Moyle W, Creedy D. Reducing dementia-related aggressio n through a staff 
education intervention. Dementia. 2007;6(2):271- 286. 
84. Downs M, Turner S, Bryans M, et al. Effectiveness of educational interven tions in improving detection 
and management of dementia in primary care: cluster randomised co ntrolled study. BMJ. 
2006;332(7543):692- 696. 
85. Monette J, Champoux N, Monette M, et al. Effect of an interdisciplina ry educational program on 
antipsychotic prescribing among nursing home residents with dementia. Int J Geriatr Psychiatry. 
2008;23(6):574-579. 
86. Ray WA, Taylor JA, Meador KG, et al. Reducing Antipsychotic Drug Use in Nur sing Homes: A 
Controlled Trial of Provider Education. Arch Intern Med. 1993;153(6):713-721. 
87. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. A Biobehavioral Home -Based Intervention 
and the Well-being of Patients With Dementia and Their Caregivers. JAMA: The Journal of the 
American Medical Association. 2010;304(9):983-991. 
88. Fortinsky RH, Gitlin LN, Pi[INVESTIGATOR_101659], et al. Translation of the Care of Persons with Dementia in their 
Environments (COPE) intervention in a publicly-funded home care cont ext: Rationale and research 
design. Contemporary clinical trials. 2016;49:155-165. 
89. Samus QM, Johnston D, Black BS, et al. A multidimensional home-based ca re coordination 
intervention for elders with memory disorders: the Maximizing Independ ence at Home (MIND) pi[INVESTIGATOR_232329]. Am J Geriatr Psychiatry. 2014;22(4):398- 414. 
90. Belle SH, Burgio L, Burns R, et al. Enhancing the quality of life of d ementia caregivers from different 
ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145(10):727-738. 
91. Nichols LO, Martindale-Adams J, Zhu CW, Kaplan EK, Zuber JK, Waters TM. Impact of the REACH II 
and REACH VA Dementia Caregiver Interventions on Healthcare Costs. J Am Geriatr Soc. 
2017;65(5):931-936. 
92. LaMantia MA, Alder CA, Callahan CM, et al. The Aging Brain Care Medical H ome: Preliminary Data. 
J Am Geriatr Soc. 2015;63(6):1209-1213. 
93. Cohen-Mansfield J, Thein K, Marx MS, Dakheel-Ali M, Freedman L. Eff icacy of nonpharmacologic 
interventions for agitation in advanced dementia: a randomized, placebo-c ontrolled trial. J Clin 
Psychiatry. 2012;73(9):1255-1261. 
94. Opie J, Doyle C, O'Connor DW. Challenging behaviours in nursing home  residents with dementia: a 
randomized controlled trial of multidisciplinary interventions. Int J Geriatr Psychiatry. 2002;17(1):6- 13. 
Study Number:  18-[ZIP_CODE]   Page 35 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  95. Pi[INVESTIGATOR_686317], Francke AL, van der Steen JT, et al. Effects of a Stepwise Multid isciplinary Intervention for 
Challenging Behavior in Advanced Dementia: A Cluster Randomized Controll ed Trial. J Am Geriatr 
Soc. 2016;64(2):261-269. 
96. Hanson LC, Zimmerman S, Song MK, et al. Effect of the Goals of Car e Intervention for Advanced 
Dementia: A Randomized Clinical Trial. JAMA Intern Med. 2017;177(1):24- 31. 
97. Hanson LC, Carey TS, Caprio AJ, et al. Improving decision-making fo r feeding options in advanced 
dementia: a randomized, controlled trial. J Am Geriatr Soc. 2011;59(11):2009- 2016.  
98. Mezey MD, Kobayashi M, Grossman S, Firpo A, Fulmer T, Mitty E. Nurses Imp roving Care to Health 
System Elders (NICHE): implementation of best practice models. J Nurs Adm. 2004;34(10):451-457. 
99. King HB, Battles J, Baker DP, et al. TeamSTEPPS: Team Strategies and Too ls to Enhance 
Performance and Patient Safety. In: Henriksen K, Battles JB, Keyes MA, Gra dy ML, eds. Advances in 
Patient Safety: New Directions and Alternative Approaches (Vol. 3: Perfor mance and Tools).  
Rockville (MD)2008. 
100. Marshall S, Harrison J, Flanagan B. The teaching of a structured too l improves the clarity and content 
of interprofessional clinical communication. Qual Saf Health Care. 2009;18(2):137-140. 
101. Volicer L, Hurley AC. Review Article: Management of Behavioral Sympt oms in Progressive 
Degenerative Dementias. The Journals of Gerontology Series A: Biological Sciences and Medical 
Sciences. 2003;58(9):M837-M845. 
102. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen fo r dementia: validation in a 
population-based sample. Journal of the American Geriatrics Society. 2003;51(10):1451-1454. 
103. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief cl inical form of the 
Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233-239. 
104. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for de pression in dementia. 
Biol Psychiatry. 1988;23(3):271-284. 
105. Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depressi on Scale: a 
comparison with the 30-item form. J Geriatr Psychiatry Neurol. 1991;4(3):173- 178. 
106. Warden V, Hurley AC, Volicer L. Development and Psychometric Evaluation of the Pain Assessment 
in Advanced Dementia (PAINAD) Scale. Journal of the American Medical Directors Association. 
2003;4(1):9-15. 
107. Robinson BC. Validation of a Caregiver Strain Index. J Gerontol. 1983;38(3):344-348. 
108. Czajkowski SM, Powell LH, Adler N, et al. From ideas to efficacy: The ORBIT  model for developi[INVESTIGATOR_268124]. Health Psychol. 2015;34(10):971- 982. 
109. Corbeil RR, Quayhagen MP, Quayhagen M. Intervention Effects on Demen tia Caregiving Interaction: 
A Stress-Adaptation Modeling Approach. J Aging Health. 1999;11(1):79- 95. 
110. Zwakhalen SM, Hamers JP, Peijnenburg RH, Berger MP. Nursing staff kno wledge and beliefs about 
pain in elderly nursing home residents with dementia. Pain Res Manag. 2007;12(3):177-184. 
111. Davison TE, McCabe MP, Mellor D, Karantzas G, George K. Knowledge of  late-life depression: an 
empi[INVESTIGATOR_457612]. Aging & Mental Health. 2009;13(4):577- 586. 
112. Cohen-Mansfield J, Jensen B, Resnick B, Norris M. Knowledge of and Attitu des Toward 
Nonpharmacological Interventions for Treatment of Behavior Symptoms Asso ciated With Dementia: A 
Comparison of Physicians, Psychologists, and Nurse Practitioners. The Gerontologist. 2011. 
113. Costabile MF, Marsico MD, Lanzilotti R, Plantamura VL, Roselli T. On the Usa bility Evaluation of E-
Learning Applications. Paper presented at: Proceedings of the 38th Ann ual Hawaii International 
Conference on System Sciences; 6-[ADDRESS_930330], Satele D, Shanafelt T. Ability of a 9-Item Well-Being Index to I dentify Distress and Stratify 
Quality of Life in US Workers. J Occup Environ Med. 2016;58(8):810-817. 
116. Dyrbye LN, Johnson PO, Johnson LM, Satele DV, Shanafelt TD. Efficacy of th e Well-Being Index to 
Identify Distress and Well-Being in US Nurses. Nursing research. 2018;67(6):447-455. 
117. SAS/STAT Statistical Analysis Software  [computer program]. Version 9.3. Cary, NC: SAS Institute, 
Inc.,; 2013. 
  
Study Number:  18-[ZIP_CODE]   Page 36 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  19 Attachments 
These documents are relevant to the protocol, but they are not considered  part of the protocol.  They are 
stored and modified separately. As such, modifications to these documen ts may not require protocol 
amendments. 
 
• Consent Language for Survey-Clinician 
• Application for Waiver of authorization and consent-PWD 
• Application for Waiver of Documentation of Consent-Clinicians 
• Vulnerable Populations: Cognitive Impaired Subject Appendix 
• Dementia Symptom Knowledge Assessment-Clinicians 
• Home Health Aide Assessment-Clinicians 
 
[ADDRESS_930331] of a dementia care expert care program on burnout, job satisfaction and tu rnover rate for 
interdisciplinary hospi[INVESTIGATOR_686318]: To evaluate the influence of the Aliviado dementia care training on profession al quality of life and well-being of 
the hospi[INVESTIGATOR_686319]:  
1. To examine the association between a dementia care expert care program on burnout, job satisfa ction and 
turnover rate for interdisciplinary hospi[INVESTIGATOR_686320]:  
2. To explore interdisciplinary hospi[INVESTIGATOR_686321]’ experiences with burnout, job sati sfaction and turnover when 
providing care to persons with dementia  
Mixed Methods Aim :  
3. Compare the qualitative results to findings from the quantitative surveys (ProQOL and well-being)  and gain 
insight into the reasons behind varying scores  
 
Background 
Hospi[INVESTIGATOR_686322], pain management, and emotional and spi[INVESTIGATOR_270830] l support tailored to 
individuals living with a terminal illness [1]. In 2016, 1.43 million Medicare beneficia ries were enrolled in hospi[INVESTIGATOR_686323]; among which 18% had a principal diagnosis of dementia [1]. A s the dementia progresses, persons 
with dementia (PWD) tend to display a plethora of behavioral changes, collectively termed Be havioral and Psychological 
Symptoms of Dementia (BPSD). Research conducted with professional caregi vers of PWDs showed that understanding 
PWDs’ behavior and behavioral change is a crucial factor to achieve and sus tain good working relationships between 
professionals and PWDs receiving care [2]. Helpi[INVESTIGATOR_686324], and subsequently improve hospi[INVESTIGATOR_154261]’s 
professional quality of life (QoL). Research also shows that the role of homecare worker s supporting PWDs up to the end 
of life remains under-researched, with unmet needs for informational, technic al and emotional support [3]. The Aliviado 
Dementia Care-Hospi[INVESTIGATOR_686325] a toolbox to hospi[INVESTIGATOR_686326]. To understand the potential impact of the Alivia do Dementia Care-Hospi[INVESTIGATOR_686327]’s professional QoL, we propose the addition of the following measures that will be collected at the existing 
baseline survey, and during a new [ADDRESS_930332] methodology in pi[INVESTIGATOR_2268] 2 desc ribed in the 
primary study. Quantitative survey questions from the validated instruments outlined below will be inse rted in the 
existing baseline survey. A new, optional, 6 month survey timepoint will be added, with  an additional option at  the end 
Study Number:  18-[ZIP_CODE]   Page 37 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  of the 6 month  survey to check a box stating they would be interested in participating in a telephonic based qualitati ve 
interview. 
 
Quantitative Measures 
 
The quantitative measurements that will be used to evaluate burnout and job satisfaction inclu de: 
1) Professional Quality of Life (ProQOL-5) —The ProQOL is a [ADDRESS_930333] 30 days. The scale starts at one indi cating never 
and goes to five indicating very often. It measures professional quality of life on three subscales i ncluding 
compassion satisfaction, burnout and secondary traumatic stress. Higher scores on the burnout a nd secondary 
traumatic stress indicate higher risk for burnout and higher secondary traumatic stress, respe ctively. Higher 
scores on the compassion satisfaction scale indicate greater satisfaction in your abi lity to be an effectiv e 
caregiver at your job (Stamm, 2009 & 2010).  
a. The concise ProQOL manual . Pocatello, ID. Retrieved from ProQOL. org . 
https://proqol.org/ProQol_Test.html    (See measure below P.2) 
2) 9-item Well-being Index (WBI) —The WBI is an index used to identify U.S. workers in distress and stratify 
quality of life. The WBI is a successful screening tool to identify distress and identify those  with high well-
being among nurses (Dyrbye, Johnson, Johnson, Satele & Shanafelt, 2019) and among a variety of workers 
(Dyrbye, Satele & Shanafelt, 2016).  
a. Retreived from https://www.mededwebs.com  request form.  (See measure below P. 5).  
3) Supplemental questions asked will include:  
a. National Sample Survey of Registered Nurses question numbers: 36, 66, 67,  
b. Retention Question: Do you plan to be with your current employer one year from now?  
Yes or No 
 
Qualitative Measures 
 
Qualitative Interview. Example questions in the table below.  
Questions Follow Up Probes Comments/Field Observations 
Tell me about your experience 
with the Aliviado training What did you expect to gain from 
the training?  
What part of the training was most 
helpful? 
Any barriers or facilitators to 
completing the online training? 
  
Tell me about your ability to 
care for persons with dementia 
(PWD) in the hospi[INVESTIGATOR_686328]?  
What changes have you 
experienced in your job after the 
training?  
  
Tell me about your satisfaction 
with your current professional 
role responsibilities How has the training influenced 
your feelings of compassion? 
How much stress do you experience 
daily at work?  
How has your stress changed since 
the training?  
  
Tell me about how you feel 
about being able to provide How much patience do you have 
when you provide care for PWD?   
Study Number:  18-[ZIP_CODE]   Page 38 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19  compassionate care on a daily 
basis How do you feel your job supports 
your ability to provide 
compassionate care?  
 
What aspects of your job or 
patient caseload impact your 
ability to carry out your job?  How are these aspects influencing 
your desire to stay in your current 
role?   
Is there anything else you 
would like to share that I did 
not ask about?    
 
 
 
All qualitative interviews will conducted by [CONTACT_686349]. Transcripts will be crea ted from the recordings. 
 
Inclusion/Exclusion Criteria 
Per Primary Study 
 
Number of Subjects 
Quantitative: Per Primary Study 
Qualitative:  
 
Analytic Plan 
Survey data will be analyzed quantitively. Descriptive and frequency statistics w ill be used to demographic data. Paired 
T-test will be used to analyze between pre and post survey results. Data fr om qualitative interviews will be coded using 
open coding methodology. The team members will code the interviews separate ly and will compare coding to reach 
interrater reliability. Codes will then be merged into categories. From the c ategories themes will be identified. A similar 
team member checking will also occur during the development of categories and themes.  
 
Participant Burden 
This ancillary study will include [ADDRESS_930334]-training and will occur at the convenience of the 
participant over the phone by [CONTACT_686350]. Answering these questions will take approximately 45- 60 mi nutes.  
 
Participant Incentives 
Participants will receive a $[ADDRESS_930335] for completing the 6-month survey, and an additional $[ADDRESS_930336] for completing 
the telephonic interview. 
 
Consent Procedures 
The existing informational header for the quantitative surveys (waiver of w ritten documentation) has been updated to 
reflect the addition of this ancillary study. A separate waiver of written consent will be  requested for the qualitative study. 
During the qualitative interview, potential subjects will be emailed the informationa l header ahead of time and telephone 
consent will be performed (see waiver of written documentation-ancillary study request).  
 
Data Safety 
All data downloaded from the survey system will be maintained in accordance w ith the Data Safety Plan as outlined above 
and in concordance with NYULH data management policies. All identified data will be maintained on t he MCIT research 
mounted drive. All de-identified data will be maintained on NYU Box per NYU campus data security protocol s. 
 
Potential Risks and Benefits 
This ancillary study presents no greater risk that the original study (minima l risk). The greatest risk is of loss of 
confidentiality. Prior experience with these measures have not found to caus e any harm, and data will not be provided back 
to the subjects’ employer. There are no potential benefits to the subjec t, but generalized knowledge will be obtained that 
can potentially assist in reducing hospi[INVESTIGATOR_686329]. 
 
 
Study Number:  18-[ZIP_CODE]   Page 39 
Version Date: 3.28.19    
CONFIDENTIAL  
This material is the property of the NYU School of Medi cine and Langone Medical Center.  Do not disclose or use  except as authorized in 
writing by [CONTACT_553748]: 3.28.19   
 
 
 
 